KCNA3 and Alzheimer disease: To address these knowledge gaps regarding Kv1.3 as a therapeutic target in AD, we performed flow cytometric studies to determine the pattern of Kv1.3 channel expression in 5xFAD and aging mice and tested the in-vivo efficacy of the ShK analog ShK-223 in acute neuroinflammatory and AD mouse models.